Bio-Rad Laboratories BBIO.B.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Bio-Rad Laboratories B (BIO.B.N) trades at a P/E of 43.80x, P/B of 1.36x, P/S of 3.76x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 72nd percentile over the trailing 10Y window (vs. 67th percentile over 3Y); P/B sits at the 36th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/S sits at the 48th percentile over the trailing 10Y window (vs. 93rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 78th percentile within its industry and the 82nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.03%, ranking at the 90th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 35.9 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Bio-Rad Laboratories B operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: BIO.B · BIO.B
Want the full picture on whether Bio-Rad Laboratories B (BIO.B.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 43.80 | ||||||
| P/B (MRQ) | 1.36 | ||||||
| P/S (TTM) | 3.76 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 3.03% |